ReviewCureus2025
Risk of Perihippocampal Recurrence After Hippocampal Avoidance in Prophylactic Cranial Irradiation: A Literature Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A standard practice in the treatment of patients with small-cell lung cancer (SCLC) is prophylactic cranial irradiation (PCI) to reduce the chance of brain metastases. However, whole brain radiation therapy (WBRT) has been associated with concerns about neurocognitive decline. This has led to the development of WBRT techniques with the simultaneous avoidance of the hippocampus (HA). This article reviews the existing literature on the incidence of hippocampal failure after HA PCI in patients with SCLC. The effort to protect the hippocampus aims to reduce side effects at a cognitive level, but, as reported in various studies, the results regarding safety and effectiveness are ambiguous. Some indicate a higher risk of recurrence in the hippocampal and perihippocampal regions, particularly in non-oligometastatic patients. Despite any concerns, many trials have shown that HA in PCI significantly reduces cognitive decline without compromising overall survival or control of brain metastases. The mixed results noted between studies indicate the necessity of clinical trials to elucidate the benefits and risks of PCI with simultaneous hippocampal protection in patients suffering from SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.